Orion PharmaDHA:ORIONPHARM +3.02%71 Days Payable is 592.37 as of Mar. 2026, which is 266% above its 10-year median of 161.85. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 391 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 92.33% on this metric.
The historical rank and industry rank for Orion Pharma's Days Payable or its related term are showing as below:
DHA:ORIONPHARM'
s Days Payable Range Over the Past 10 Years
Min: 32.7 Med: 161.85 Max: 875.27
Current: 875.27
During the past 12 years, Orion Pharma's highest Days Payable was 875.27. The lowest was 32.70. And the median was 161.85.
DHA:ORIONPHARM's Days Payable is ranked better than 92.33% of 391
companies
in the Utilities - Independent Power Producers industry
Industry Median: 79.51
vs DHA:ORIONPHARM: 875.27
Orion Pharma's Days Payable
declined
from Mar. 2025 (1,199.67) to Mar. 2026 (592.37).
It may suggest that Orion Pharmaaccelerated paying its suppliers.
Orion Pharma Days Payable Related Terms
Orion Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Days Payable Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Days Payable vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Orion Pharma's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Days Payable of 592.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orion Pharma and its competitors. This is 266% above median its historical median of 161.85. Over the past decade, Orion Pharma's Days Payable has ranged from 32.70 to 875.27. According to the industry distribution chart, Orion Pharma ranks #30 out of 391 companies in the Utilities - Independent Power Producers industry, placing it in the top 7.7%.
Is Orion Pharma's Days Payable too high?
Orion Pharma's current Days Payable of 592.37 is 266% above median its 10-year median of 161.85. Over the past 10 years, this metric has ranged from a low of 32.70 to a high of 875.27. The Utilities - Independent Power Producers industry median Days Payable is 79.51. Orion Pharma's value of 592.37 is 645% above this industry median. Based on the distribution chart, Orion Pharma ranks #30 out of 391 companies in the Utilities - Independent Power Producers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Days Payable compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #30 out of 391 companies for Days Payable. This places Orion Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 79.51. Orion Pharma's value of 592.37 is 645% above this benchmark. Historically, Orion Pharma's own Days Payable has ranged from 32.70 to 875.27 over the past decade. While the company's 10-year median is 161.85 vs. the industry median of 79.51, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for an Utilities - Independent Power Producers company?
The median Days Payable among Utilities - Independent Power Producers companies is 79.51, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Days Payable of 592.37 is 645% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Days Payable is 79.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Days Payable is 592.37, which is 266% above median its own 10-year median of 161.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current Days Payable is 592.37, which is 266% above median its 10-year median of 161.85 and 645% above the Utilities - Independent Power Producers industry median of 79.51. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Days Payable is 592.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Days Payable: 592.37 (266% above median its 10-year median of 161.85)
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
Industry Position: 645% above the Utilities - Independent Power Producers median (#30 of 391)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
